This biotechnology company develops 3D human tissue models for drug discovery and development. Their platform creates self-assembled, matrigel-free 3D models that offer more accurate and predictive results than traditional 2D cell cultures, enabling researchers to more effectively identify and test drugs.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional 2D cell cultures often fail to accurately mimic the complex microenvironment of human tissues, leading to inaccurate and unreliable results in drug discovery and development. This can result in ineffective drug candidates progressing through preclinical and clinical trials, increasing costs and delaying the availability of new therapies.
Solution
Bonds Biosystems provides 3D human tissue models, branded as 3D BioSol™, that offer a more physiologically relevant platform for drug discovery and development compared to traditional 2D cell cultures. These self-assembled, matrigel-free 3D models more accurately replicate the in vivo environment, enabling researchers to identify and validate drug candidates with greater confidence. The company offers platforms for studying obesity, cardiotoxicity, and pulmonary hypertension, providing tailored solutions for specific disease areas. By using these 3D models, researchers can improve the accuracy and predictability of their results, leading to more efficient drug development processes.
Target Audience
The primary customers are pharmaceutical companies, biotechnology companies, and academic research institutions involved in drug discovery and development.
Features
- Self-assembled, matrigel-free 3D human tissue models
- 3D BioSol™ technology for creating physiologically relevant microenvironments
- Platforms for studying obesity, cardiotoxicity, and pulmonary hypertension
- Contract research services utilizing the 3D tissue models
- Ability to create custom 3D tissue models tailored to specific research needs